Jane Fonda is an incredibly strong woman who has been open and candid about her health over the years. The actress and ...

Rutherrin(R), when combined with a common diabetic drug and radiation, was able to effectively destroy Non-Hodgkin's Lymphoma ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Melissa Coulier, co-founder of Live Well Lead Well, uses holistic wellness to aid Dave's cancer journey and help others ...

The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

more than 3,500 patients in the U.S. with this aggressive form of non-Hodgkin lymphoma experience treatment failure or ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...

Julie Hart Schutte, a longtime friend of Deckert and fellow Kiwanis Club member, said people are naturally drawn to Deckert. “And I’ll tell you what, it’s not just because she’s a good friend, but she ...

FDA clears LTZ's IND application to initiate trial of its myeloid engager immunotherapy to treat relapsed or refractory non-Hodgkin lymphoma.